Nicholas Galakatos Net Worth: Estimate, Breakdown, Sources

Nicholas Galakatos is a prominent life sciences investor and the Global Head of Blackstone Life Sciences. Based on publicly available insider trading data aggregated by Benzinga, his detectable net worth from reported share holdings comes to approximately $223,000 as of May 19, 2026. That figure, however, almost certainly understates his real wealth significantly. It only captures what shows up in SEC insider trading filings and does not account for his private equity carried interest, fund compensation, or any assets that are not publicly reported. A more realistic range for someone at his career level and tenure at Blackstone would be in the tens of millions of dollars, though an exact figure cannot be confirmed from public data alone.

Which Nicholas Galakatos are we talking about?

There is one Nicholas Galakatos who stands out clearly in public records: Dr. Nicholas (Nick) Galakatos, PhD, a biotech and life sciences investor based in the Boston area. His career trail is unusually well documented. He earned a PhD in Organic Chemistry from MIT, did a postdoctoral fellowship at Harvard Medical School, and completed his undergraduate degree at Reed College. He co-founded Clarus Ventures in 2005 and served as its Managing Director before Blackstone acquired Clarus in December 2018. After that acquisition, he became Global Head of Blackstone Life Sciences and chairs the division's investment committees. He is also a director at Neurvati and has served in board roles at various biotech companies. His SEC CIK number is 0001252522, which ties him to insider trading filings across multiple biotech companies including Entasis Therapeutics and Tourmaline Bio (formerly Talaris Therapeutics).

There is one meaningful disambiguation note. A federal court case captioned 'Galakatos v. Marsh & McLennan Companies' appeared in the District of Massachusetts docket in February 2025 and reached the First Circuit (docket 25-1282). It is not confirmed whether this plaintiff is the same Dr. Nicholas Galakatos from Blackstone or a different individual sharing the name. If you are researching the Blackstone investor specifically, the SEC CIK 0001252522 and the Blackstone career profile are the right anchors to use. Any net worth figure attached to a different person named Nicholas Galakatos should not be applied to the Blackstone investor. Because of that, you should also be careful with searches for Nicholas Saputra net worth, since that can refer to a different individual entirely Any net worth figure attached to a different person named Nicholas Galakatos should not be applied to the Blackstone investor..

The current net worth estimate: what the numbers actually show

Benzinga's insider trading profile for CIK 0001252522 (Nicholas Galakatos) puts his estimated net worth at $223,000, last updated May 19, 2026. Benzinga derives this number entirely from reported share positions disclosed in SEC Form 4 filings. It also notes there are 'no significant net worth' signals from those numbers alone. That is an honest admission that the methodology is narrow. SEC Form 4 filings only capture publicly traded equity positions that must be disclosed because of insider status. They do not capture private fund carry, salary, bonuses, privately held investments, or real estate.

A more grounded estimate requires thinking about what someone in his position likely earns and holds. Blackstone Life Sciences manages funds in the multi-billion dollar range. As of March 2026, Blackstone raised $6.3 billion for its latest life sciences fund. As reported by Bloomberg Law, a March 2026 news item about Blackstone Life Sciences described Blackstone Life Sciences led by Nicholas Galakatos blank" rel="noopener noreferrer">March 2026 news item about Blackstone Life Sciences led by Nicholas Galakatos. Senior partners and fund heads at firms like Blackstone typically earn base salaries in the hundreds of thousands annually, bonuses that can multiply that figure several times over, and carried interest (a share of fund profits) that can produce wealth in the tens of millions over a career. Given that Galakatos co-founded Clarus in 2005, has been active in biotech investing for over two decades, and now leads one of the largest life sciences investment platforms in the world, a conservative personal wealth range of $20 million to $80 million would be a reasonable working estimate. But that range is model-based, not verified from documents, and should be treated accordingly. If you are specifically looking for Nicholas Naples net worth, treat any figure you see as another model-based estimate unless it is tied to verifiable filings and compensation records net worth estimate.

Where to look: the best public sources for verification

If you want to get as close to a verified figure as possible today, these are the sources worth checking in order of reliability.

1. SEC EDGAR (CIK 0001252522): Search for all Form 3, Form 4, and Form 5 filings under this CIK. These disclose equity positions in publicly traded companies where Galakatos is an insider. The most recent filing on SEC Info was a Form 3 filed May 6, 2021, but EDGAR may have more recent entries. Check directly at edgar.sec.gov for the latest.
2. GuruFocus insider profile: GuruFocus aggregates SEC insider trading history and can give you a chronological view of reported trades. It is estimate-driven but useful for cross-checking what Benzinga shows.
3. Blackstone's official 'Our People' page and fund filings: These confirm his current role and, indirectly, his involvement in fund vehicles. Formds.com and similar aggregators list him as an executive in specific Blackstone Life Sciences fund entities, which helps map his compensation structure even if actual figures are not disclosed.
4. Public fund raising announcements: Bloomberg Law and BioCentury have reported on Blackstone Life Sciences fund closings. The size of funds he oversees is a proxy for the scale of carry and compensation involved.
5. Court records (with caution): The Galakatos v. Marsh & McLennan docket may or may not be the same person. If it is, litigation filings sometimes surface financial detail inadvertently, but verify identity before treating it as relevant.

Breaking down where his wealth likely comes from

Even without a confirmed total number, it is useful to understand what categories of wealth are most likely for someone with Galakatos's career profile. The breakdown below reflects typical wealth structures for senior biotech/private equity investors at this level.

The carried interest angle is particularly important. When Blackstone acquired Clarus in 2018, Galakatos and the Clarus team would have received consideration from that acquisition. The exact terms were not publicly disclosed, but acquisition payouts at this scale in the life sciences space are commonly structured in the millions of dollars for founding partners. That one event alone could represent a meaningful portion of his accumulated wealth, separate from anything he has earned since.

How the net worth picture has likely shifted over time

Tracing the timeline helps put the current estimate in context. Galakatos co-founded Clarus Ventures in 2005. Over the 13 years before the Blackstone acquisition, Clarus deployed capital across multiple funds, which would have generated carried interest as portfolio companies matured or were acquired. The Blackstone acquisition in December 2018 was a liquidity and career-defining moment. Since then, he has overseen a significant ramp-up in assets under management. Blackstone's life sciences platform has grown considerably, with the March 2026 fund close at $6.3 billion representing one of the larger pools of capital in the sector.

On the SEC insider trading side, the record shows activity tied to companies like Entasis Therapeutics (2019) and Tourmaline Bio (formerly Talaris Therapeutics). These are the kinds of biotech board positions that generate stock-based compensation reported on Form 4. The fact that the detectable figure is only around $223,000 from these filings suggests most of his wealth sits in private structures, not publicly traded holdings subject to insider reporting. This pattern is common for private equity executives whose primary compensation is fund-based rather than listed-company equity.

How reliable is the $223,000 figure, and what are the red flags?

The Benzinga figure of $223,000 is technically verifiable because it is based on disclosed SEC filings, but it is almost certainly not a complete picture of net worth. If you are specifically looking for Nicholas Stella net worth, the key takeaway is that most of the Blackstone-linked wealth is private and not captured by public insider trading disclosures $223,000. It is the floor of what can be confirmed, not a ceiling or a best estimate of total wealth. The methodology has real limitations that are worth understanding.

• SEC Form 4 only captures equity positions in public companies where the filer is a statutory insider (officer, director, or 10%+ shareholder). Private fund interests, LP stakes, and personal investments are invisible to this system.
• Benzinga's own language acknowledges 'no significant net worth' from these numbers, which is a signal that the aggregator itself knows the figure is incomplete.
• Sites that show dramatically different numbers (say, $5 million or $50 million) without citing specific documents or methodology are guessing. Without a primary source, those numbers are speculation dressed up as data.
• The 'last updated' timestamp (May 19, 2026) reflects when the aggregator last refreshed, not when new underlying data was filed. Always check EDGAR directly for the actual filing dates.
• Real estate data is not linked to him in available records. The Waltham, MA address on his Form 4 is a corporate office address, not a personal residence, so it cannot be used to infer property wealth.

The honest bottom line: anyone who gives you a precise, confident net worth number for Nicholas Galakatos beyond what SEC filings show is estimating based on career benchmarks, not documents. That includes this site. The $20 million to $80 million range cited earlier is a reasonable industry-informed estimate, but it is not verified. Justia contracts records also show leases involving 35 Gatehouse Drive in the legal record, though the page does not by itself confirm how that relates to Nicholas Galakatos personally versus a company entity blank" rel="noopener noreferrer">35 Gatehouse Drive, Waltham, MA. Nicholas Veniamin Net Worth is often discussed in the same context as other life sciences investors, but those figures can be easy to mix up or misattribute. Use it as a starting point for context, not a conclusion.

What to do right now to verify or update the number

If you need the most current and defensible estimate possible as of today (June 24, 2026), here is a practical workflow. For a focused look at Nicholas Georgiade net worth, you can compare how other public indicators and disclosures stack up against typical compensation in similar roles.

1. Go to EDGAR full-text search at efts.sec.gov and search for CIK 0001252522. Pull every Form 4, Form 3, and Schedule 13G or 13D filing. Note the companies, share quantities, and transaction prices. This is your verified baseline.
2. Cross-reference on GuruFocus and Benzinga to confirm your reading of those filings matches what the aggregators report. If there is a discrepancy, trust the EDGAR source documents.
3. Search for proxy statements (DEF 14A filings) from any public company where Galakatos serves as a director. These often disclose director compensation including cash fees and equity grants, which adds to the picture.
4. Check Bloomberg Law, BioCentury, and Reuters for any recent news about Blackstone Life Sciences fund closings or personnel changes. Fund size and role changes are meaningful proxies for compensation trajectory.
5. Search court records via Justia or PACER for the Galakatos v. Marsh & McLennan case (First Circuit docket 25-1282) and confirm whether it involves the same individual. If it does, monitor filings for any financial disclosures.
6. If this is for a professional purpose (due diligence, journalism, or legal research), consider a commercial data provider like PitchBook, Preqin, or Refinitiv that tracks private equity compensation and carry structures with more depth than public filings alone.

For context within this site's broader coverage of notable Nicholases: Galakatos is an unusual profile compared to figures like Nicholas Goulandris (shipping and art world wealth) or Nicholas Saputra (entertainment income), because his wealth is almost entirely embedded in private institutional finance structures. If you are also comparing other investors, Nicholas Goulandris net worth is often discussed because of his wealth tied to shipping and art holdings Nicholas Goulandris (shipping and art world wealth). That makes it harder to verify, but the career evidence is unusually well documented for a private equity executive, which at least gives a solid foundation for estimation. The core identity is not in question. It is the number that requires caution.